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Abstract (246 words; max. 250) 25 
 26 
Upon release of HIV-1 particles from the infected cell, the viral protease cleaves 27 
the Gag polyprotein at specific sites, triggering maturation.  During this process, 28 
which is essential for infectivity, the capsid protein (CA) reassembles into a 29 
conical core.  Maturation inhibitors (MIs) block HIV-1 maturation by interfering 30 
with protease-mediated CA-SP1 processing and by stabilizing the immature CA-31 
SP1 lattice; virions from MI-treated cells retain an immature-like CA-SP1 lattice, 32 
whereas mutational abolition of cleavage at the CA-SP1 site results in virions in 33 
which the CA-SP1 lattice converts to a mature-like form. We previously reported 34 
that propagation of HIV-1 in the presence of MI PF-46396 selected for assembly-35 
defective, compound-dependent mutants with amino acid substitutions in the 36 
major homology region (MHR) of CA. Propagation of these mutants in the 37 
absence of PF-46396 resulted in the acquisition of second-site compensatory 38 
mutations. These included a Thr-to-Ile substitution at SP1 residue 8 (T8I), which 39 
results in impaired CA-SP1 processing.  Thus, the T8I mutation phenocopies PF-40 
46396 treatment in terms of its ability to rescue the replication defect imposed by 41 
the MHR mutations, and to impede CA-SP1 processing.  Here, we use cryo-42 
electron tomography to show that, like MIs, the T8I mutation stabilizes the 43 
immature-like CA-SP1 lattice.  These results have important implications for the 44 
mechanism of action of HIV-1 MIs; they also suggest that T8I may provide a 45 
valuable tool for structural definition of the CA-SP1 boundary region, which has 46 
thus far been refractory to high-resolution analysis apparently because of 47 
conformational flexibility in this region of Gag. 48 
49 
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Importance (135 words; max. 150) 50 
 51 
HIV-1 maturation involves dissection of the Gag polyprotein by the viral protease, 52 
and assembly of a conical capsid enclosing the viral ribonucleoprotein. 53 
Maturation inhibitors (MIs) prevent the final cleavage step at the site between the 54 
capsid protein (CA) and the spacer peptide 1 (SP1), apparently by binding at this 55 
site and denying the protease access. Additionally, MIs stabilize the immature-56 
like CA-SP1 lattice, preventing release of CA into the soluble pool. We previously 57 
found that a mutation in SP1, T8I, rescues a PF-46396-dependent CA mutant 58 
and blocks CA-SP1 cleavage. In this study, we imaged T8I virions by cryo-59 
electron tomography and show that T8I mutants, like MI-treated virions, contain 60 
an immature CA-SP1 lattice. These results lay the groundwork needed to 61 
understand the structure of the CA-SP1 interface region and further illuminate the 62 
mechanism of action of MIs. 63 
64 
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Introduction 65 
 66 
The production of HIV-1 particles is driven primarily by the Gag precursor protein, 67 
Pr55Gag, in concert with cellular factors.  Pr55Gag is composed of several major 68 
domains and spacer peptides, organized, from N- to C-terminus: matrix (MA), 69 
capsid (CA), spacer peptide 1 (SP1), nucleocapsid (NC), spacer peptide 2 (SP2), 70 
and p6.  During Gag translation, an infrequent ribosomal frameshifting event 71 
leads to the synthesis of the larger GagPol polyprotein, Pr160GagPol, which 72 
additionally contains the viral protease (PR), reverse transcriptase (RT), and 73 
integrase (IN) (1, 2).  74 
As the immature virion buds off from the infected cell, the PR is activated 75 
and dissects the Gag and GagPol precursor polyproteins. The Gag cleavage 76 
sites are processed in a specific order ((3, 4); Fig. 1). Cleavage starts at the SP1-77 
NC site, detaching the viral nucleoprotein complex (vRNP; NC plus genomic 78 
RNA) from the residual Gag shell. This is followed by cleavage at the MA-CA 79 
site, separating CA from the membrane-bound MA layer; and finally, by cleavage 80 
between CA and SP1. Upon its liberation from the Gag precursor, CA is released 81 
into a soluble pool from which a conical capsid is assembled (here, we use the 82 
term capsid to denote the assembled CA protein shell and the term core for the 83 
capsid plus whatever it may contain). Although both the immature and mature CA 84 
lattices are predominantly hexameric, the strain induced by curvature in the 85 
immature lattice is accommodated by gaps in the lattice (5-7), whereas the 86 
mature capsid is organized on the basis of fullerene geometry, in which a 87 
hexameric lattice is closed by 12 vertices thought to be occupied by CA 88 
pentamers (8). 89 
High-resolution structures have been obtained for the individual Gag domains 90 
MA, CA, NC and p6 (1, 2).  However, the structure of full-length Pr55Gag has not 91 
been defined, owing to its large size and the flexible nature of the inter-domain 92 
linker regions. Of particular importance to the present study is the region where 93 
CA connects to SP1.  Peptides corresponding to this region adopt a helical 94 
conformation in vitro (9, 10), and cryo-ET studies have suggested that SP1 forms 95 
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a six-helix bundle connecting the CA lattice to the less-ordered NC/RNA layer (7, 96 
11, 12).  However, its conformation(s) in ordered lattices remain(s) poorly 97 
resolved (12).  This is a point of great interest, as the CA-SP1 boundary region is 98 
thought to be the binding site for HIV-1 maturation inhibitors (MIs; see below). 99 
By generating cleavage-preventing point mutations at salient sites in Gag, it 100 
has been shown that initiation of disassembly of the immature-like CA lattice 101 
requires cleavage on both sides of CA-SP1 (i.e., at the MA-CA and SP1-NC 102 
sites), while assembly of a core also requires cleavage between CA and SP1 103 
(13). An immature-like “thick” (~10 nm) conformation of the CA shell is found in 104 
mutants in which the MA-CA or the SP1-NC cleavage events are prevented (13). 105 
Strikingly, when CA-SP1 cleavage is completely blocked by mutagenesis (e.g., in 106 
the CA5 mutant (14)), the CA shell was found in a mature-like “thin” (~8 nm) 107 
conformation (11, 13, 15), implying that, under these conditions, the immature-108 
like CA lattice can progressively convert to a mature-like lattice without 109 
disassembling (15).  However, such viral particles are not infectious. 110 
PR inhibitors act by binding the enzyme and preventing it from cleaving its 111 
target sites in Pr55Gag and Pr160GagPol.  A different class of compounds, MIs, 112 
prevents maturation by binding to the partially processed Gag lattice and blocking 113 
the conversion of CA-SP1 to mature CA (16, 17).  Two chemically distinct 114 
maturation inhibitors have been reported: bevirimat (16-18) and PF-46396 (PF96) 115 
(19, 20).  Virions produced from MI-treated cells display a morphology 116 
characterized by an eccentric electron-dense aggregate, presumably composed 117 
of NC plus viral RNA (21), and an incomplete shell of CA-SP1 underlying the MA 118 
layer (16).  The morphology of MI-treated virions is somewhat reminiscent of that 119 
displayed by virions in which CA-SP1 cleavage has been blocked by mutations, 120 
as in CA5 (14), with two notable differences: (1) while MIs partially prevent CA-121 
SP1 cleavage, the CA5 mutant completely abolishes it; and (2) the residual Gag 122 
shell in MI-treated particles is immature-like (thick) whereas that observed in 123 
virions defective for CA-SP1 cleavage is mature-like (thin) (11, 15). Therefore we 124 
concluded that, in addition to blocking partially (but sufficiently) CA-SP1 125 
cleavage, MIs also stabilize the immature-like CA shell (11, 15).  Clinical trials 126 
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with bevirimat demonstrated that the compound is safe and effective (22, 23); 127 
however, polymorphisms, located predominantly between SP1 residues 6 and 8, 128 
reduced susceptibility of HIV-1 to the compound in a significant percentage of 129 
treated patients (24-26). 130 
Propagation of HIV-1 in culture in the presence of PF96 led to the selection of 131 
resistance mutations around the CA-SP1 cleavage site (20), where resistance to 132 
bevirimat maps (27).  Resistance mutations also arose far upstream in CA in the 133 
major homology region (MHR), a highly conserved retroviral sequence known to 134 
be important for virus assembly (20). Replication of the MHR mutants was 135 
markedly PF96-dependent (20).  The replication defect exhibited by the PF96-136 
dependent MHR mutants (e.g., CA-P157S) could be rescued not only by PF96 137 
but also by second-site substitutions in Gag that arose spontaneously during 138 
propagation of these mutants in the absence of compound.  One such mutation 139 
was a Thr-to-Ile substitution at residue 8 of SP1 (T8I). Notably, on its own, the 140 
T8I mutant was severely replication-defective and displayed an accumulation of 141 
CA-SP1. Thus, in two important respects, the T8I mutation phenocopies the 142 
effect of PF96 binding: 1) it interferes with CA-SP1 processing; and 2) it rescues 143 
the assembly defect imposed by the CA-P157S MHR mutation.   144 
These observations led us to hypothesize that the T8I mutation, like MIs, may 145 
stabilize the immature CA-SP1 lattice.  By coupling T8I with the cleavage-146 
defective mutant CA5 and examining the resulting virus particles by cryo-ET, we 147 
demonstrate that T8I does indeed stabilize the immature CA-SP1 lattice. These 148 
results extend the parallels between MI binding and the T8I mutation and further 149 
suggest that the T8I mutation may offer a valuable tool for resolving the structure 150 
of the highly flexible SP1 region.  151 
152 
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MATERIALS AND METHODS 153 
 154 
Plasmids.  The pNL4-3 molecular clone (28), and the T8I (20) and CA5 ((14); 155 
kindly provided by H.-G. Kräusslich) derivatives have been reported previously.  156 
The CA5/T8I double mutant was constructed by site-directed mutagenesis using 157 
the Quikchange method (Stratagene) following the manufacturer’s instructions.  158 
 159 
Infectivity and CA-SP1 processing assays. Single-cycle infectivity assays 160 
were performed by using the TZM-bl indicator cell line (obtained from J. Kappes 161 
through the NIH AIDS Reagent Program; (29)) as previously described (30).  162 
Briefly, 293T cells were transfected with WT pNL4-3 or derivatives containing the 163 
indicated Gag mutations.  Virus stocks were harvested, filtered, normalized for 164 
RT activity, and used to infect TZM-bl cells.  Two days post-infection, luciferase 165 
activity was measured.  To monitor CA-SP1 accumulation (27, 31), HeLa cells 166 
transfected with the indicated HIV-1 molecular clones were metabolically labeled 167 
with [35S]-Met/Cys for 2 hr one day post-transfection.  Virus-containing 168 
supernatants were harvested, filtered, and subjected to ultracentrifugation at 169 
75,000 x g for 45-60 min.   Virus pellets were resuspended in lysis buffer (31) and 170 
characterized by SDS-PAGE.  CA and CA-SP1 bands were quantified by 171 
phosphorimager analysis using Quantity One software (Biorad). 172 
 173 
Cryo-ET and subtomogram averaging.  These operations were performed 174 
essentially as previously described (32). In brief, paraformaldehyde-fixed virus 175 
was mixed (2:1) with 10-nm colloidal gold particles (Aurion, Wageningen, The 176 
Netherlands), applied to Quantifoil R2/2 holey carbon grids, and plunge-frozen in 177 
a Vitrobot (FEI, Hillsboro, OR). Grids were then transferred to a cryo-holder (type 178 
626; Gatan, Warrendale, PA), and single-axis tilt series were recorded on a 179 
Tecnai-12 electron microscope (FEI) equipped with an energy filter (GIF 2002; 180 
Gatan). The microscope was operated at 120 keV in zero-loss mode with an 181 
energy slit width of 20 eV. Images were acquired using SerialEM (33) and 182 
recorded on a 2,048- by 2,048-pixel CCD camera (Gatan). Tilt-series were 183 
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acquired at 2º intervals from ~ -66º to ~ 66º, at an electron dose of ~1.1 e-/Å2 per 184 
projection (total cumulative dose ~75 e-/Å2). The magnification used was 38,500x 185 
(0.78-nm/pixel) and the nominal defocus was -4 µm (first contrast transfer 186 
function zero at (3.7 nm)-1). Tilt series images were aligned and reconstructed 187 
using the Bsoft package (34), and virions were extracted and denoised by 20 188 
iterations of anisotropic nonlinear diffusion (35). The in-plane resolution of the 189 
tomograms was 5.0 to 5.5 nm for individual virions as calculated by the NLOO-190 
2D (noise-compensated leave one out in two dimensions) method (36).  191 
Subtomograms containing structures of interest (subvolumes containing patches 192 
of Gag-related lattice, 39 nm on a side) were located manually in the denoised 193 
virions and extracted from the corresponding raw reconstructions of the virion. 194 
Initial orientations of the patches were defined by vectors from the virion centers 195 
directed radially outwards, thus approximately perpendicular to the viral 196 
envelope. A density map calculated by averaging all selected patches was then 197 
generated, cylindrically symmetrized, and used as a reference for translationally 198 
aligning all subtomograms. Subtomogram alignment was done taking into 199 
account the missing wedge of information (37), performed with routines from 200 
Bsoft (38) modified as needed and wrapped into Python scripts. The procedure 201 
was repeated two more times, using the average from the preceding cycle as 202 
reference for the next cycle. As a result of this process, subtomograms were 203 
translationally but not rotationally aligned, and therefore the Gag-related lattices 204 
were not yet in register. For the next steps the viral membrane and MA layers 205 
were masked off to maximize the influence of the Gag-related lattice. One 206 
subtomogram was selected, C6 symmetry was applied, and this subvolume was 207 
used as a reference to rotationally and translationally align the other patches. 208 
This alignment procedure was iterated 5 times, using as reference the average of 209 
the top ~5-10% of the particles (as ranked by correlation coefficients) from the 210 
previous round. Classification and averaging were then performed by maximum 211 
likelihood as implemented in the Xmipp package (39). Approximately the top 33% 212 
of the initially selected subtomograms were used to calculate the final average. 213 
The percentage of data excluded in subtomogram averaging usually ranges from 214 
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45% to 60% (12, 40). In this study, the results obtained with, respectively, 70% 215 
and 50% exclusion were very similar but we elected to use the former analysis 216 
because it made the CA repeat slightly clearer. 217 
Two preparations each of WT, T8I and CA5, and three of CA5-T8I, were imaged 218 
by cryo-EM, and the results obtained were consistent in each case. Cryo-ET was 219 
performed on one preparation for WT and T8I, two for CA5 and three for CA5-220 
T8I. 221 
222 
 10 
Results and Discussion 223 
 224 
The T8I mutation impairs CA-SP1 processing and inhibits HIV-1 infectivity.  225 
To measure the infectivity of the T8I mutant in a single-round assay, 293T cells 226 
were transfected with the WT molecular clone pNL4-3 (28) or the mutants CA5 227 
(14), T8I (20) and CA5/T8I.  Infectivity was measured in the TZM-bl indicator cell 228 
line (29) (Fig. 2A). These results indicated that the infectivity of T8I was 229 
approximately 15% that of WT.  As shown previously (14, 30), the CA5 mutant, 230 
which has two substitutions that completely block CA-SP1 processing was non-231 
infectious, as was a CA5/T8I double mutant (Fig. 2A).  Effects of the CA5, T8I, 232 
and CA5/T8I mutations on CA-SP1 processing were confirmed by metabolic 233 
radiolabeling (Fig. 2B).  T8I virions showed an approximately 70% accumulation 234 
of CA-SP1, whereas CA5 and CA5/T8I mutants were completely blocked for CA-235 
SP1 processing; only CA-SP1 and no mature CA was detected.  By contrast, WT 236 
virions showed only ~5-10% accumulation of CA-SP1. No differences in the 237 
amounts of uncleaved Gag or any other CA-containing cleavage products were 238 
found. 239 
 240 
Cryo-ET analysis reveals that the T8I mutation stabilizes the immature Gag 241 
lattice.  HIV-1 virions imaged by cryo-ET can be classified according to core 242 
morphology as being conical (Fig. 3A & D), non-conical (Fig. 3B & E), or having 243 
no core (Fig. 3C & F), and by the presence (Fig. 3D-F) or absence (Fig. 3A-C) of 244 
a partial CA-SP1 lattice (an “inner shell”) underneath and somewhat offset from 245 
the viral envelope (i.e., the bilayer plus MA layer).  246 
Most (~80%) WT virions possess a conical core and none of them contains 247 
an inner shell (Fig. 3G; for example Fig. 3A). In contrast, most virions produced in 248 
the presence of MIs lack conical cores – they are present in only ~6% of BVM-249 
treated and ~13% of PF96-treated virions – but contain an inner shell (found in 250 
~82% of BVM-treated and in ~56% of PF96-treated virions) (11, 15). As 251 
previously demonstrated, in MI-treated virions this inner shell is in the immature-252 
like/thick conformation (11, 15). Additionally, MI-treated virions that lack a core 253 
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often contain an electron-dense “eccentric condensate” similar to those observed 254 
when virions are produced in the presence of allosteric IN inhibitors (ALLINIs) or 255 
in class II IN mutants (41). The eccentric condensates observed in ALLINI-256 
treated preparations have been demonstrated to be the vRNP (21). 257 
As with MIs, the T8I mutation reduces the percentage of virions with conical 258 
cores – in this case, to ~31% (representative examples of T8I mutants are shown 259 
in Fig. 4A-D). Moreover, a significant fraction of the T8I particles (~32%) contain 260 
an inner shell whose extent can vary but on average is only about half that of the 261 
original Gag shell (Figs. 3G & 4D-F). Also, as with MI-treated virions, the T8I 262 
inner shells are mostly in the immature-like “thick” conformation (Fig 4D-F), 263 
although in ~10% of cases the Gag shell appears to be in the mature-like “thin” 264 
conformation (Fig. 4 G & H). A small fraction of these virions (3% of T8I particles 265 
containing a CA-SP1 shell) present a mosaic of thick and thin CA-SP1. An 266 
alternative explanation for the occasional mature-like shell in T8I virions is that 267 
they could represent malformed cores.  268 
One difference between T8I and MI-treated virions is that T8I produces more 269 
virions that lack a core [~28% for T8I, compared to ~1% in BVM-treated and ~2% 270 
in PF96-treated virions (15)]. As in BVM- and PF-96-treated virions, most (~90%) 271 
of these T8I particles contain RNPs packed in eccentric condensates (e.g. Fig 4 272 
E & F). The basis for the difference in the percentage of particles lacking a core 273 
that is observed with T8I vs. MI-treated virions is currently unknown. 274 
As previously described (11, 15), almost all (~82%) CA5 virions contain an 275 
un-eroded CA-SP1 shell (Figs. 3G, 4J & K). (The Gag shells of immature virions 276 
have a sizable gap at the budding site, around which we infer that erosion takes 277 
place after Gag processing, to account for the less complete CA-SP1 shells 278 
observed after MI-treatment or with the T8I mutant). The CA-SP1 shells of CA5 279 
virons are mostly in the mature-like (thin-walled) conformation (Fig. 4J & K), 280 
although in a few cases (~3% of the CA-SP1 containing particles) they present a 281 
mosaic of thick and thin regions (Fig. 4L). The mosaic arrangement was 282 
previously found in CA5 virions treated with the MI PF96, and was suggested to 283 
represent an intermediate step in a displacive in situ transformation of the CA-284 
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SP1 shell (15). However, this pseudo-maturation process does not generate 285 
bona fide capsids and does not produce infectious particles (15). When CA5 286 
virions are produced in the presence of BVM or PF96, the inner shell remains in 287 
the immature-like (thick-walled) conformation, consistent with the ability of MIs to 288 
prevent the immature-to-mature transition.  289 
To determine whether the T8I mutation is able, like MIs, to stabilize the 290 
immature-like CA-SP1 lattice, we combined the T8I and CA5 mutations and 291 
examined the resulting virions by cryo-ET. As we had previously seen with MI-292 
treated CA5 virions (15), the CA5/T8I particles exhibited the thick, immature-like 293 
Gag shells (Fig. 4 M-P).  294 
To enhance the features of the immature-like CA-SP1 shell, subtomogram 295 
averaging was performed on T8I, CA5 and CA5/T8I mutant virions (Fig. 5). 296 
These data confirm that the CA shell from T8I and CA5/T8I mutants is organized 297 
as a honeycomb lattice, similar to that from immature and MI-treated virions (11, 298 
15), although there may be small differences between them that are not 299 
detectable at the current resolution. Additionally, SP1 is seen as a faint 300 
connecting density, again in agreement with previous results. The CA5 CA-SP1 301 
shell does not exhibit a regular pattern, most likely because it has a flatter 302 
surface topography. This is consistent with what is observed in the immature-to-303 
mature conformational change occurring in the CA5 CA-SP1 lattice (15).  304 
 305 
Summary. In conclusion, cryo-ET and subtomogram averaging confirm and 306 
extend the hypothesis that the T8I mutation has similar effects on maturation to 307 
those of MIs. This mutation rescues the replication defect conferred by PF96-308 
dependent MHR mutations (20), impedes CA-SP1 processing, and results in the 309 
stabilization of immature-like CA-SP1 shells. Given that residue 8 of SP1 lies 310 
outside the PR recognition sequence (which involves several amino acids on 311 
either side of the cleavage site), this mutation may disrupt CA-SP1 processing by 312 
stiffening SP1, which may need to be flexible for efficient CA-SP1 processing.  313 
The striking parallels between the effects of MI binding and the T8I mutation 314 
suggest that MIs may likewise disrupt CA-SP1 processing not only by binding to 315 
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the cleavage site and preventing access by PR, but also by restricting the 316 
conformational flexibility around the CA-SP1 junction. The ability of the T8I 317 
mutation to stabilize the immature-like Gag shell further suggests that this mutant 318 
will be a useful tool for resolving the structure of the highly disordered SP1 319 
domain of Gag in the context of virus particles and for understanding the effect of 320 
MI binding on Gag structure.   321 
 322 
 323 
Acknowledgements 324 
We thank members of the Freed and Steven laboratories for helpful discussion 325 
and critical review of the manuscript. This work is supported by the Intramural 326 
Research Programs of the Center for Cancer Research, National Cancer 327 
Institute, NIH (E.O.F) and of the National Institute of Arthritis and Musculoskeletal 328 
and Skin Diseases, NIH (A.C.S.) and by the Intramural AIDS Targeted Antiviral 329 
Program (E.O.F and A.C.S.). 330 
331 
 14 
References 332 
 333 
1. Freed EO. 2015. HIV-1 assembly, release and maturation. Nat Rev 334 
Microbiol 13:484-496. 335 
2. Sundquist WI, Kräusslich HG. 2012. HIV-1 assembly, budding, and 336 
maturation. Cold Spring Harb Perspect Med 2:a006924. 337 
3. Konvalinka J, Kräusslich HG, Müller B. 2015. Retroviral proteases and 338 
their roles in virion maturation. Virology 479-480:403-417. 339 
4. Lee S-K, Potempa M, Swanstrom R. 2012. The choreography of HIV-1 340 
proteolytic processing and virion assembly. J Biol Chem 287:40867-341 
40874. 342 
5. Briggs JA, Riches JD, Glass B, Bartonova V, Zanetti G, Kräusslich 343 
HG. 2009. Structure and assembly of immature HIV. Proc Natl Acad Sci U 344 
S A 106:11090-11095. 345 
6. Fuller SD, Wilk T, Gowen BE, Kräusslich HG, Vogt VM. 1997. Cryo-346 
electron microscopy reveals ordered domains in the immature HIV-1 347 
particle. Curr Biol 7:729-738. 348 
7. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, Sundquist WI, 349 
Jensen GJ. 2007. Electron cryotomography of immature HIV-1 virions 350 
reveals the structure of the CA and SP1 Gag shells. EMBO J 26:2218-351 
2226. 352 
8. Li S, Hill CP, Sundquist WI, Finch JT. 2000. Image reconstructions of 353 
helical assemblies of the HIV-1 CA protein. Nature 407:409-413. 354 
9. Datta SA, Temeselew LG, Crist RM, Soheilian F, Kamata A, Mirro J, 355 
Harvin D, Nagashima K, Cachau RE, Rein A. 2011. On the role of the 356 
SP1 domain in HIV-1 particle assembly: a molecular switch? J Virol 357 
85:4111-4121. 358 
10. Morellet N, Druillennec S, Lenoir C, Bouaziz S, Roques BP. 2005. 359 
Helical structure determined by NMR of the HIV-1 (345-392)Gag 360 
sequence, surrounding p2: implications for particle assembly and RNA 361 
packaging. Protein Sci 14:375-386. 362 
11. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC. 2011. 363 
HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J 364 
Virol 85:1420-1428. 365 
12. Schur FK, Hagen WJ, Rumlova M, Ruml T, Muller B, Kräusslich HG, 366 
Briggs JA. 2015. Structure of the immature HIV-1 capsid in intact virus 367 
particles at 8.8 A resolution. Nature 517:505-508. 368 
13. de Marco A, Muller B, Glass B, Riches JD, Kräusslich HG, Briggs JA. 369 
2010. Structural analysis of HIV-1 maturation using cryo-electron 370 
tomography. PLoS Pathog 6:e1001215. 371 
14. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Kräusslich 372 
HG. 1998. Sequential steps in human immunodeficiency virus particle 373 
maturation revealed by alterations of individual Gag polyprotein cleavage 374 
sites. J Virol 72:2846-2854. 375 
 15 
15. Keller PW, Huang RK, England MR, Waki K, Cheng N, Heymann JB, 376 
Craven RC, Freed EO, Steven AC. 2013. A two-pronged structural 377 
analysis of retroviral maturation indicates that core formation proceeds by 378 
a disassembly-reassembly pathway rather than a displacive transition. J 379 
Virol 87:13655-13664. 380 
16. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, 381 
Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed 382 
EO, Wild CT. 2003. PA-457: a potent HIV inhibitor that disrupts core 383 
condensation by targeting a late step in Gag processing. Proc Natl Acad 384 
Sci U S A 100:13555-13560. 385 
17. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken 386 
C, Chen CH. 2004. Small-molecule inhibition of human immunodeficiency 387 
virus type 1 replication by specific targeting of the final step of virion 388 
maturation. J Virol 78:922-929. 389 
18. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto 390 
T, Sano K, Nakashima H. 2001. Anti-human immunodeficiency virus 391 
activity of YK-FH312 (a betulinic acid derivative), a novel compound 392 
blocking viral maturation. Antimicrob Agents Chemother 45:1225-1230. 393 
19. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, Jackson RL, 394 
Murray E, Patick AK, Peng Q, Perros M, Pickford C, Wu H, Butler SL. 395 
2009. New small-molecule inhibitor class targeting human 396 
immunodeficiency virus type 1 virion maturation. Antimicrob Agents 397 
Chemother 53:5080-5087. 398 
20. Waki K, Durell SR, Soheilian F, Nagashima K, Butler SL, Freed EO. 399 
2012. Structural and functional insights into the HIV-1 maturation inhibitor 400 
binding pocket. PLoS Pathog 8:e1002997. 401 
21. Fontana J, Jurado KA, Cheng N, Ly NL, Fuchs JR, Gorelick RJ, 402 
Engelman AN, Steven AC. 2015. Distribution and Redistribution of HIV-1 403 
Nucleocapsid Protein in Immature, Mature, and Integrase-inhibited Virions: 404 
A Role for Integrase in Maturation. J Virol doi:10.1128/JVI.01522-15. 405 
22. Salzwedel K, Martin DE, Sakalian M. 2007. Maturation inhibitors: a new 406 
therapeutic class targets the virus structure. AIDS Rev 9:162-172. 407 
23. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, 408 
Allaway GP, Martin DE. 2007. Phase I and II study of the safety, virologic 409 
effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-410 
dimethylsuccinyl)betulinic acid (bevirimat) against human 411 
immunodeficiency virus infection. Antimicrob Agents Chemother 51:3574-412 
3581. 413 
24. Adamson CS, Sakalian M, Salzwedel K, Freed EO. 2010. 414 
Polymorphisms in Gag spacer peptide 1 confer varying levels of 415 
resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology 7:36. 416 
25. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, 417 
Martin D, Salzwedel K, Allaway G. 2008. HIV-1 Gag polymorphisms 418 
determine treatment response to bevirimat (PA-457). Antiviral Therapy 419 
13:A10-A10. 420 
 16 
26. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, 421 
Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ. 2009. 422 
Susceptibility of human immunodeficiency virus type 1 to the maturation 423 
inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer 424 
peptide 1. Antimicrob Agents Chemother 53:2185-2188. 425 
27. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, 426 
Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO. 427 
2006. In vitro resistance to the human immunodeficiency virus type 1 428 
maturation inhibitor PA-457 (Bevirimat). J Virol 80:10957-10971. 429 
28. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, 430 
Martin MA. 1986. Production of acquired immunodeficiency syndrome-431 
associated retrovirus in human and nonhuman cells transfected with an 432 
infectious molecular clone. J Virol 59:284-291. 433 
29. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu 434 
X, Shaw GM, Kappes JC. 2002. Emergence of resistant human 435 
immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) 436 
monotherapy. Antimicrob Agents Chemother 46:1896-1905. 437 
30. Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO. 2010. 438 
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-439 
negative inhibitor of HIV-1 maturation. Virology 400:137-144. 440 
31. Waheed AA, Ono A, Freed EO. 2009. Methods for the study of HIV-1 441 
assembly. Methods Mol Biol 485:163-184. 442 
32. Fontana J, Steven AC. 2013. At low pH, influenza virus matrix protein M1 443 
undergoes a conformational change prior to dissociating from the 444 
membrane. J Virol 87:5621-5628. 445 
33. Mastronarde DN. 2005. Automated electron microscope tomography 446 
using robust prediction of specimen movements. J Struct Biol 152:36-51. 447 
34. Heymann JB, Cardone G, Winkler DC, Steven AC. 2008. Computational 448 
resources for cryo-electron tomography in Bsoft. J Struct Biol 161:232-449 
242. 450 
35. Frangakis AS, Hegerl R. 2001. Noise reduction in electron tomographic 451 
reconstructions using nonlinear anisotropic diffusion. J Struct Biol 452 
135:239-250. 453 
36. Cardone G, Grunewald K, Steven AC. 2005. A resolution criterion for 454 
electron tomography based on cross-validation. J Struct Biol 151:117-129. 455 
37. Frank J. 2006. Electron Tomography: Methods for Three-Dimensional 456 
Visualization of Structures in the Cell. 457 
38. Heymann JB, Belnap DM. 2007. Bsoft: image processing and molecular 458 
modeling for electron microscopy. J Struct Biol 157:3-18. 459 
39. Scheres SH, Melero R, Valle M, Carazo JM. 2009. Averaging of electron 460 
subtomograms and random conical tilt reconstructions through likelihood 461 
optimization. Structure 17:1563-1572. 462 
40. Zanetti G, Briggs JAG, Grunewald K, Sattentau QJ, Fuller SD. 2006. 463 
Cryo-electron tomographic structure of an immunodeficiency virus 464 
envelope complex in situ. Plos Pathogens 2. 465 
 17 
41. Engelman A. 1999. In vivo analysis of retroviral integrase structure and 466 
function. Adv Virus Res 52:411-426. 467 
42. Lanman J, Lam TT, Emmett MR, Marshall AG, Sakalian M, Prevelige 468 
PE, Jr. 2004. Key interactions in HIV-1 maturation identified by hydrogen-469 
deuterium exchange. Nat Struct Mol Biol 11:676-677. 470 
43. de Marco A, Heuser AM, Glass B, Kräusslich HG, Muller B, Briggs JA. 471 
2012. Role of the SP2 domain and its proteolytic cleavage in HIV-1 472 
structural maturation and infectivity. J Virol 86:13708-13716. 473 
474 
 18 
Table 1. Subtomogram averaging information. 475 
 476 
 No. of 
tomograms 
No. of 
virions 
No. of selected 
subtomograms 
No. of averaged 
subtomograms 
Average 
resolution (nm) 
(FSC 0.5 cut-
off) 
Spacing of hexagonal 
lattice (nm) 
T8I 9 49 730 248 4.4 7.8 
CA5 3 40 1097 385 3.9 N/A 
CA5-T8I 7 169 6035 2079 3.7 7.8 
 477 
478 
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Figure legends 479 
 480 
Figure 1.  Schematic diagram of the HIV-1 Gag cleavage and maturation 481 
process. WT virions mature through the 4 stages shown on the top row, with ~ 482 
95% of them assembling a capsid, of which 80-85% are conical (top row, right 483 
diagram). (In the remaining ~5%, which lack a core, all of CA stays in the soluble 484 
pool; top row, third diagram). In MI-treated virions (11, 15), much of the CA 485 
(typically, 50% or so (42)) remains in an immature-like lattice (bottom row, left 486 
diagram). In CA5 virions, in which CA-SP1 cleavage is completely blocked, the 487 
CA shell progresses to a mature-like conformation (bottom row, right diagram). 488 
Bottom left: Blow-up showing the SP1 sequence, with the secondary cleavage 489 
site marked with an arrowhead. Note that SP2 and p6 (distal to NC (4, 43)) are 490 
not included in these diagrams.  491 
 492 
Figure 2. Effect of CA5, T8I, and CA5/T8I mutations on virus infectivity and 493 
CA-SP1 processing. (A) Viruses were produced in 239T cells by transfecting 494 
with WT or mutant pNL4-3 molecular clones. Virus-containing supernatants were 495 
normalized for RT activity and used to infect TZM-bl cells. The luciferase signal 496 
was normalized to the corresponding RT values. Error bars indicate standard 497 
deviations from 3 independent experiments. (B) HeLa cells were transfected with 498 
pNL4-3 WT, CA5, T8I, and CA5/T8I and were metabolically labeled with 499 
[35S]Met/Cys. Released virions were collected by ultracentrifugation and virion-500 
associated CA and CA-SP1 were analyzed by SDS-PAGE and quantified by 501 
phosphorimager analysis. A representative gel image is shown on the top and 502 
quantification of the % CA-SP1 relative to total CA + CA-SP1 is presented in the 503 
graph. Error bars indicate standard deviations from five independent 504 
experiments.  505 
 506 
Figure 3. Cryo-ET analysis of WT virions and T8I, CA5 and CA5/T8I mutants. 507 
Tomographic central sections (A-F) and distribution, in percentages (G), of HIV 508 
virions classified according to core morphology and the presence or absence of 509 
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an inner shell of density. The panels show chosen representative images from 510 
HIV WT (A) and the T8I mutant (B to F) used in this study. CA-SP1 inner shells 511 
are labeled with white arrowheads. The numbers in bold correspond to the 512 
majority species for each sample, and help identifying which panels represent the 513 
samples analyzed in the study. Scale bar, 50 nm.  514 
 515 
Figure 4. Tomographic sections of T8I, CA5 and CA5/T8I mutants. A-H, 516 
tomographic sections of T8I virions. A-D illustrate the distribution of the 517 
morphologies seen in T8I virions: A, conical core; B & D, non-conical core; C, no 518 
core; A-C, no inner shell; D, contains inner shell. E-F illustrate T8I virions with 519 
inner CA-SP1 shells: in ~90% of cases the inner shell is immature-like (E & F; 520 
see also D); and in ~10% of cases it is in a mature-like conformation (G & H). I-L, 521 
tomographic sections of CA5 mutants. I, non-conical core and no inner shell; J-K, 522 
no core, but containing an inner shell in mature-like conformation; L, tomographic 523 
section from one of the rare (~ 3%) CA5 virions containing a mosaic 524 
immature/mature inner shell of CA-SP1. M-P, tomographic sections of CA5/T8I 525 
virions with no core and immature-like CA-SP1 inner shell.  White arrowheads, 526 
immature-like CA-SP1 shell; black arrowheads, mature-like CA-SP1 shell; white 527 
arrows, eccentric condensates. Scale bar, 50 nm. 528 
 529 
 530 
Figure 5.  Subtomogram averaging of the CA-SP1 inner shell of density. A-531 
C, sections through the 3D maps. Top row, radial sections; central row, in-plane 532 
section at the height of CA (black arrowhead); bottom row, in-plane section at the 533 
height of SP1 from the immature-like shells (white arrowhead). The arrows in the 534 
top panels label the faint densities corresponding to SP1. To enhance the signal 535 
from the CA-SP1 layer, the viral membrane and MA layer were not used during 536 
subtomogram aligning and classification; as a result, they are not resolved in the 537 
final average. This suggests that the distance between the CA-SP1 shell and MA 538 
is not constant, in agreement with the fact that cleavage between MA and CA has 539 
taken place. D, top view surface renderings the CA-SP1 lattices of CA5/T8I (gold, 540 
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solid) and of T8I (blue, mesh). To compare with the CA-SP1 lattice from WT 541 
protease-defective virions, the reader is referred to Keller et al., 2011 and 2013 542 
(11, 15). Scale bar, 10 nm.  543 
 544 
